Edgewise Therapeutics Files 8-K

Ticker: EWTX · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1710072

Edgewise Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyEdgewise Therapeutics, Inc. (EWTX)
Form Type8-K
Filed DateJun 26, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, reporting

Related Tickers: EDGW

TL;DR

EDGW files 8-K, standard reporting, no new news.

AI Summary

Edgewise Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates Edgewise Therapeutics is meeting its reporting obligations with the SEC, but it does not disclose any new material information that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for reporting purposes and does not contain any new material information that would suggest increased risk.

Key Players & Entities

  • Edgewise Therapeutics, Inc. (company) — Registrant
  • June 26, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 001-40236 (identifier) — SEC File Number
  • 82-1725586 (identifier) — IRS Employer Identification No.
  • 1715 38th St. Boulder, CO 80301 (address) — Address of principal executive offices
  • 720-262-7002 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for Edgewise Therapeutics, Inc.?

The primary purpose is to report on other events and financial statements as of June 26, 2025, fulfilling regulatory requirements.

When was the earliest event reported in this filing?

The earliest event reported was on June 26, 2025.

What is Edgewise Therapeutics, Inc.'s state of incorporation?

Edgewise Therapeutics, Inc. is incorporated in Delaware.

What is the SEC file number for Edgewise Therapeutics, Inc.?

The SEC file number for Edgewise Therapeutics, Inc. is 001-40236.

Where are Edgewise Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 1715 38th St. Boulder, CO 80301.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding Edgewise Therapeutics, Inc. (EWTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.